Platelets in Patients with Premature Coronary Artery Disease Exhibit Upregulation of miRNA340* and miRNA624*

Brigitte M. Sondermeijer1, Annemiek Bakker1, Amalia Halliani2, Maurice W. J. de Ronde1, Arnoud A. Marquart3, Anke J. Tijsen2, Ties A. Mulders1, Maayke G. M. Kok1, Suzanne Battjes1, Steffi Maiwald1, Suthesh Sivapalaratnam1, Mieke D. Trip1, Perry D. Moerland4, Joost C. M. Meijers1, Esther E. Creemers2, Sara-Joan Pinto-Sietsma1,4*

1 Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 2 Heart Failure Research Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 3 Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 4 Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Abstract

**Background:** Coronary artery disease (CAD) is the leading cause of human morbidity and mortality worldwide, underscoring the need to improve diagnostic strategies. Platelets play a major role, not only in the process of acute thrombosis during plaque rupture, but also in the formation of atherosclerosis itself. MicroRNAs are endogenous small non-coding RNAs that control gene expression and are expressed in a tissue and disease-specific manner. Therefore they have been proposed to be useful biomarkers. It remains unknown whether differences in miRNA expression levels in platelets can be found between patients with premature CAD and healthy controls.

**Methodology/Principal Findings:** In this case-control study we measured relative expression levels of platelet miRNAs using microarrays from 12 patients with premature CAD and 12 age- and sex-matched healthy controls. Six platelet microRNAs were significantly upregulated (miR340*, miR451, miR454*, miR545:9.1, miR615-5p and miR624*) and one miRNA (miR1280) was significantly downregulated in patients with CAD as compared to healthy controls. To validate these results, we measured the expression levels of these candidate miRNAs by qRT-PCR in platelets of individuals from two independent cohorts; validation cohort I consisted of 40 patients with premature CAD and 40 healthy controls and validation cohort II consisted of 27 patients with artery disease and 40 healthy relatives. MiR340* and miR624* were confirmed to be upregulated in patients with CAD as compared to healthy controls in both validation cohorts.

**Conclusion/Significance:** Two miRNAs in platelets are significantly upregulated in patients with CAD as compared to healthy controls. Whether the two identified miRNAs can be used as biomarkers and whether they are cause or consequence of the disease remains to be elucidated in a larger prospective study.

Citation: Sondermeijer BM, Bakker A, Halliani A, de Ronde MWJ, Marquart AA, et al. (2011) Platelets in Patients with Premature Coronary Artery Disease Exhibit Upregulation of miRNA340* and miRNA624*. PLoS ONE 6(10): e25946. doi:10.1371/journal.pone.0025946

Editor: Pieter H. Reitsma, Leiden University Medical Center, The Netherlands

Received April 26, 2011; Accepted September 14, 2011; Published October 13, 2011

**Copyright:** © 2011 Sondermeijer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This research was supported by institutional funding of the Academic Medical Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** S.J.P. and E.E.C. are inventors on a filed patent application owned by the Academic Medical Center that details claims related to the described miRNAs (Title: Means and methods for determining risk of cardiovascular disease. Number: 10160635.8). The authors confirm that this does not alter their adherence to all the PLoS One policies on sharing data and materials.

* E-mail: S.J.Pinto@amc.uva.nl

Introduction

Coronary artery disease (CAD) is the leading cause of human morbidity and mortality worldwide, underscoring the need for innovative diagnostic strategies. Prevention of CAD relies on the accurate identification of individuals at risk of developing CAD. At present CAD risk estimation is based on the assessment of established risk factors using one of the available risk assessment algorithms[1]. However, risk estimates are imprecise in predicting which subjects will develop CAD underscoring the need for innovative diagnostic strategies[2–4]. This has prompted the search for novel diagnostics that can improve the identification of individuals at risk of developing CAD. We propose that, in this respect, microRNAs (miRNAs) could be highly useful. MiRNAs are a class of endogenous short (~22 nucleotides), single-stranded and non-coding RNA molecules, which can affect the expression of many mRNAs. They exert coordinated and potent effects on cell function[5,6] and are implicated in human diseases[7] including cardiovascular diseases (CVD) [8,9]. According to current estimates, the human genome is estimated to encode up to 500 miRNAs[10], many of which are expressed in a tissue- and cell-specific manner[11–14], making them attractive biomarkers for diagnostic strategies.

Activated platelets play a critical role in the pathophysiology of CAD in the process of acute thrombosis which follows plaque
rupture, as well as in chronic plaque formation[15]. This is exemplified by the beneficial effects of anti-platelet therapy in both the acute and chronic phases of the disease. MiRNAs are known to be present in platelets and exert important regulatory functions[16], since platelets also harbour Dicer and Argonaute 2 (Agö2) complexes, which are involved in the processing of miRNA precursors and the control of specific transcripts. Until recently, miRNAs were thought to be present only in tissue and therefore the use of these molecules as biomarkers for CAD would be less practical. It is now clear that miRNAs are also present in the circulation in nucleated blood cells and even in plasma[17,18] and non-nucleated cells, such as erythrocytes[19] and platelets[16,20-23], making them easily accessible.

Given the importance of platelets in CAD, we hypothesized that platelets from patients manifest different miRNA expression patterns in CAD patients compared to controls. Therefore, we examined the expression levels of platelet miRNAs in patients with CAD and compared them with healthy individuals.

Methods

Study populations

The array cohort. For the miRNA array study population we selected a cohort of 12 Caucasian male patients with CAD at a young age (premature CAD) and a positive family history of premature cardiovascular disease (CVD), see Definitions S1. These patients are genetically predisposed for CAD leading to a substantial risk for CAD[23]. The patients were selected from the outpatient clinic of the Academic Medical Center (AMC) of Amsterdam, which is specialised in premature CAD. Data collection was done 3.9±2.0 years after the diagnosis of CAD.

The control cohort was composed of 12 healthy Caucasian male volunteers, who were recruited by advertisement and who were matched with the cases for age and smoking habits. Individuals of this control cohort did not have a history of CVD, nor did they have a positive family history of CVD and they were not allowed to use any medication. Patients and controls were excluded when they suffered from diabetes.

The validation cohorts

To validate the findings of the microarray data, we measured the expression levels of the selected miRNAs in isolated platelets in two independent validation cohorts by qRT-PCR.

Validation cohort I. Validation cohort I consisted of 40 premature male CAD subjects and 40 age-matched male controls. Participants were selected in the same way as the population used for the miRNA array analysis, using identical matching inclusion and exclusion criteria. Individuals in the control cohort were again recruited by advertisement. Data collection was done 5.6±3.5 years after the diagnosis of CAD. Inclusion took place from December 2009 to June 2010. Since miRNA expression levels are influenced by medication [24,25] we assessed miRNA expression before and after medication use. Therefore, we asked twenty-seven control subjects in this cohort, which are part of a validation cohort II, to use any medication. Patients and controls were excluded when this control cohort did not have a history of CVD, nor did they have a positive family history of CVD as biomarkers for CAD would be less practical. It is now clear that miRNAs are also present in the circulation in nucleated blood cells and even in plasma[17,18] and non-nucleated cells, such as erythrocytes[19] and platelets[16,20-23], making them easily accessible.

Given the importance of platelets in CAD, we hypothesized that platelets from patients manifest different miRNA expression patterns in CAD patients compared to controls. Therefore, we examined the expression levels of platelet miRNAs in patients with CAD and compared them with healthy individuals.

Ethics Statement

This study complies with the Declaration of Helsinki. The study protocol was approved by the Medical Ethical Commission of the AMC in Amsterdam and written informed consent was obtained from all subjects.

Peripheral blood collection and platelet isolation

Non-fasting venous blood samples were drawn without stasis from an antecubital vein, with use of a 19-gauge needle. Blood was collected in 3 trisodium citrate tubes (each 5 ml containing 0.105 M trisodium citrate, BD Vacutainer). The first sample was discarded. Immediately after blood withdrawal, the samples were centrifuged (180 g, 15 min, room temperature, no brake) to obtain platelet-rich plasma (PRP). With a polypropylene pipette, the upper layer of PRP was carefully transferred to a plastic tube to avoid leukocyte contamination. One part of acid–citrate–dextrose (ACD) buffer (0.085 M trisodium citrate, 0.11 M glucose, 0.071 M Citric acid) was added to five parts of PRP and then the PRP was centrifuged (300 g, 20 min, room temperature, no brake). The platelet-poor plasma was discarded and the platelet pellet carefully resuspended in Tyrode buffer ([136.9 mM NaCl, 2.61 mM KCl, 11.9 mM NaHCO3, 5.55 mM glucose, 2 mM EDTA, pH 6.5]). The platelet suspension was centrifuged (800 g, 20 min, room temperature, no brake). The supernatant was discarded and the platelet pellet was resuspended in 30 μl sterile phosphate buffered saline (PBS) and stored at ~80°C prior to RNA isolation. The isolated platelets were investigated by fluorescence-activated cell sorting (FACS) using monoclonal antibodies against CD45 (BD Biosciences), CD235a (DAKO) and CD61 (BD Biosciences) to identify leukocytes, erythrocytes and platelets. The purity of the isolated platelets was 99.7% by FACS analysis. For information about peripheral blood collection and platelet isolation of the validation cohorts, see Methods S1.

MiRNA arrays

MiRNA expression profiles were obtained using Illumina Human v2 MicroRNA Beadarrays according to the manufacturer’s protocol for liquid samples. The protocol was modified such that samples were extracted twice with an equal volume of acid-phenol chloroform and the column was dried for 3 min after the last washing step and before elution. Samples were concentrated from 50 μl to 12 μl, of which 5 μl was used for Illumina arrays as described below.
All data is MIAME compliant and the raw data has been deposited in the MIAME compliant database GEO, as detailed on the MGED Society website http://www.mged.org/Workgroups/MIAME/miame.html. For a more detailed description of the microarray analysis, see Methods S1.

Validating miRNA expression by real-time PCR.

The methods for expression analysis by real-time PCR and the miRNA primers sequences are described in the Methods S1.

Results

Clinical characteristics

The clinical characteristics of the miRNA array cohort and both the validation cohorts are shown in Table 1. Individuals in the array cohort had a mean age of 45.5±6.6 years and did not differ between patients and controls. The average age of onset of CAD in patients was 42±7.6 years. This cohort consisted of 12 controls and 12 selected patients with premature atherosclerosis. Half of the patients presented with a myocardial infarction and half of them with stable angina. The time of data collection was on average 3.9±2.0 years after the diagnosis of CAD.

Individuals in validation cohort I had a mean age of 51.2±4.6 years at data collection and did not differ between patients and controls. Furthermore, the average age of onset of CAD in patients was 44.9±3.8 years. This cohort consisted of 40 selected patients with premature CAD and 40 healthy age-matched controls. Half of the patients presented with a myocardial infarction and half of them with stable angina. The time of data collection was on average 5 years after the diagnosis of CAD. Smoking was significantly higher among patients as compared to controls.

In validation cohort II which was a random sample of families from our outpatient clinic and was the only cohort without a matched control group, individuals had a mean age of 46.6±15.1 years. This cohort was composed of 4 families and consisted of 27 patients and 40 healthy family members. The age of the cases and controls was 59.4±9.8 and 37.7±11.2 respectively. This was significantly different due to the fact that this cohort was composed of subjects from three generations. Furthermore, smoking and a history of hypertension were also significantly different between patients and controls (all, p<0.05). The average age of onset of CAD in patients was 50.5±9.3 years. About 30% of patients presented with myocardial infarction and 48% had stable angina. The remaining 22% had non-coronary vascular disease. The time of data collection was on average 5 years after the diagnosis of CVD.

MiRNA profiles of platelets of CAD patients

Each Illumina beadarray contained 1146 human miRNAs as annotated in the Sanger miRBase 12.0 (see Data S1). In total we identified 214 miRNAs, which where differentially expressed in platelets from CAD patients as compared to controls (Data S1). Supervised hierarchical clustering analysis of these 214 miRNAs showed distinct patterns of miRNA expression levels between CAD patients and healthy controls (figure 1). Interestingly, the hierarchical clustering analysis showed differential expression between patients with a myocardial infarction as compared to patients with stable angina. Because of the small number of subjects, this did not reach statistical significance.

Out of the 214 miRNAs identified in the microarray profiling analysis, 9 miRNAs were at least 1.5-fold upregulated and 4 miRNAs were at least 1.5 fold downregulated in patients as compared to controls. Since the hierarchical clustering data showed 1 patient to cluster within the control group and 1 control subject to cluster within the patient group, we also analysed our data without these 2 subjects, to minimize influences of these 2 misclassified subjects (figure 1, green and blue subject). After all the analysis, six out of 9 miRNAs remained significantly and more than 1.5 fold upregulated (miR340*, miR615-5p, miR545:9.1, miR451, miR454* and miR624*) and 1 out of 5 miRNA remained significantly and more than 1.5 fold downregulated (miR-1280) in both analyses (figure 2).

Table 1. Characteristics of the subjects.

|                     | Microarray Validation cohort I | Real-Time PCR Validation cohort II |
|---------------------|-------------------------------|-----------------------------------|
| Patient n = 12      | Control n = 12                | Patient n = 40                    | Control n = 40|
| Age at data collection. yrs ± SD | 45.7±6.5 45.4±7.0          | 51.4±4.7 51.0±4.6                   | 59.4±9.8 37.7±11.2*|
| Age at onset of CAD. yrs ± SD        | 42±7.6                          | 44.9±3.8                          | 50.5±9.3   |
| CAD defined as AML. n (%)            | 6 (50)                          | 20 (50)                           | 8 (30)     |
| CAD defined as stable angina. n (%)  | 6 (50)                          | 20 (50)                           | 13(48)     |
| Time from diagnosis. yrs ± SD        | 3.9±2.0                         | 5.6±3.5                           | 8.6±9.9    |
| Current Smoking. n (%)               | 1 (8)                           | 11 (28)                           | 5 (13)     | 12 (44) 11 (27.5) |
| Smoking at time of event yrs ± SD    | 4 (33)                          | 24 (60)                           | 18 (66)    |
| Packyears. yrs ± SD                 | 16.6±9.7                        | 5.9±3.8                           | 18.7±15.3  | 5.7±10.2* 4.4±22.3 6.3±9.1* |
| Hypercholesterolemia. n (%)          | 2 (17)                          | 5 (12.5)                          | 4 (14.8) 1 (2.5) |
| Hypertension. n (%)                  | 2 (17)                          | 6 (15)                            | 10 (37) 2 (5)* |
| Acetylsalicylic acid. n (%)          | 12 (100)                        | 34 (85)                           | 19 (70)    |
| Lipid lowering drugs. n (%)          | 11 (92)                         | 38 (95)                           | 19 (70) 2 (5)* |
| RAAS-inhibitor. n (%)                | 4 (33)                          | 12 (30)                           | 12 (44) 2 (5)* |
| Beta blocker. n (%)                  | 5 (42)                          | 26 (65)                           | 12 (44) 2 (5)* |

doi:10.1371/journal.pone.0025946.t001
Validation of the candidate miRNAs

Validation cohort I. The 7 differentially expressed miRNAs identified by the microarray analysis were first validated, by real-time PCR, in validation cohort I. Of the 7 miRNAs, 2 miRNAs, miR340* and miR624*, were significantly upregulated in patients as compared to controls (figure 2).

Validation cohort II. After the first validation, we validated our results in a second more general cohort of patients of our premature CAD outpatient clinic. Of the 7 miRNAs identified in the array analysis, the same 2 miRNAs; miR340* and miR624*, were significantly upregulated in patients as compared to controls (figure 2). We encountered technical difficulties in validating 2 of the 7 miRNAs. MiR615-5p and the only downregulated miRNA, miR615-3p, could not be validated, since the PCR primers for these particular miRNAs did not appear to amplify a specific product.

Medication use and platelet miRNA expression

To investigate whether medication use might have influenced the miRNA expression levels of our two candidate miRNAs, miR340* and miR624*, we also analysed the expression of these miRNAs. We compared the miRNA expression changes in the platelet miRNA of controls who took medication for 6 weeks compared to the expression levels of controls taking no medication (validation cohort I), as described in the method section; this did not change the results.

Diagnostic accuracy

When evaluating the combination of 4 candidate miRNAs, miR624* and miR340*, to be significantly upregulated in patients with CAD as compared to healthy controls. Besides, these results could be validated in two independent cohorts.

This is the first study that shows an association between platelet miRNAs and patients with CAD. Previous studies in humans have found useful circulating miRNAs as biomarkers for either an acute myocardial infarction[27–30] or coronary artery disease[31–35]. Concerning myocardial infarction, miR1[27] and miR-499[28] were both detected by array analysis of animal cardiac tissue and validated in plasma of patients with an acute myocardial infarction, by qRT-PCR methods. Only recently microarray analysis of miRNAs on peripheral blood or peripheral blood components in relation to cardiovascular disease was performed. The first study by Fichtlscherer et al.[31] investigated plasma miRNA profiles of 8 patients with CAD and 8 healthy controls. They found miR-126, miR-17 and miR-92a (endothelial miRNAs), miR-155 (inflammatory miRNA) and miR-145 (smooth-muscle miRNA) to be downregulated in patients as compared to controls. Furthermore, miR-133a and miR-208a (cardiac-muscle miRNAs) were significantly upregulated. These results could be confirmed in 2 different validation cohorts. The second study investigated whole blood miRNA arrays in relation to an acute myocardial infarction and found miR-1291 and miR-663b to have the highest sensitivity and specificity for the discrimination of cases and controls[29]. In contrast to our study, the above mentioned human studies were performed on plasma or whole blood miRNAs and not on platelet miRNAs[15].

Landry et al.[16] were the first to establish the existence and functionality of miRNA pathway components in platelets of healthy volunteers. Not only did they show that human platelets harbour an abundant and diverse array of miRNAs, further analysis revealed that they also contain the Dicer and Argonaute 2 complexes, which function in the processing of exogenous miRNA precursors and the control of specific reporter transcripts. These findings confirm previous studies reporting the presence of miRNAs in platelet rich plasma, both in healthy donors[22] and patients with polycythemia vera[20]. On the other hand, these observations might have been disturbed by leukocyte contamination. Concerning the leukocyte contamination of our study, we were able to show a platelet purity of 99.72%, therefore contamination seems highly unlikely. When comparing the identified miRNAs of Landry with our list of 30 highest expressed miRNAs of platelets in healthy controls we found that 85% of the miRNAs expressed in their study are in agreement with our study. Moreover, when comparing our 30 highest expressed miRNAs of our platelets in healthy controls with the miRNAs in platelets of healthy subjects found by Hunter et al.[21], who profiled 420 known mature miRNAs by qRT-PCR, we found an overlap of 48%. Considering the technical differences between our study and other studies in profiling methods (Illumina beadchips versus
LNA-based microarrays versus qRT-PCR) and RNA isolation methods (mirVana kit versus Trizol), this overlap is rather large, supporting the robustness of our data.

It could be argued that usage of medication in our patient population might have caused the observed differences in miRNA expression levels. We propose that this is not the case, since our validation cohort I was evaluated before and after medication use, which did not influence the results for miR340* and miR624*.

One could speculate which mRNAs are regulated by the two miRNAs identified in this study. We were, however, not able to identify any association between these miRNAs and any disease or tissue involvement.

Regarding the identification of a possible biomarker, the results of our study are limited. The relatively small differences in miRNA expression levels between controls and patients make it unlikely that these miRNAs will serve as independent biomarkers. On the other hand, a combination of low expressing biomarkers might exert good prognostic value. Indeed Meder et al. identified a unique signature of 20 miRNAs that predicted acute myocardial infarction with higher power and accuracy than any single miRNA [29]. With our analysis of the combination of 4 candidate miRNAs, miR340*, miR624*, miR451 and miR454*, we found a diagnostic accuracy of AUC = 0.71, This is in the same range as the diagnostic accuracy of the Framingham risk score (FRS), showing that during a 10-year follow-up the FRS was associated with CVD with an AUC of 0.68 up to 0.77, depending on the investigated population [36].

In conclusion we show that, years after the onset of CAD, different platelet miRNA expression patterns exist between patients and controls. These platelet miRNAs can potentially fine-tune expression of specific gene products that may be involved in governing platelet reactivity. Therefore, a dysfunctional miRNA-based regulatory system could lead to the development of serious platelet-related cardiovascular diseases. Whether the two identified miRNAs can be used as biomarkers and whether they are cause or consequence of the disease remains to be elucidated in a larger prospective study, since the miRNA array profiling took place after the event in all populations.

Supporting Information

Definitions S1 Definitions with regard to the subjects. (DOC)

Methods S1 Expanded methods. (DOC)

Data S1 Names of the depicted 214 differentially expressed miRNAs (adjusted P<0.05). FC: fold change. (DOC)
Acknowledgments

We thank Marianne Schaap for her help with the platelet isolation and fluorescence-activated cell sorting.

Author Contributions

Conceived and designed the experiments: JCMM EEC SJPS. Performed the experiments: BMS AB AH MWjDr AAM AJT TAM MGMK SB SS MDT. Analyzed the data: BMS AB PDM. Contributed reagents/materials/analysis tools: AH AAM AJT EEC. Wrote the paper: BMS AB PDM. Acquired data: MWJdR TAM MGMK SB SS MDT. Provided critical materials/analysis tools: AH AAM AJT EEC. Contributed reagents/materials/analysis tools: AH AAM AJT EEC. Final approval of the version to be published: BMS AB AH MWjDr AAM AJT TAM MGMK SB SS MDT PDM JCMM EEC.

References

1. Ferken BS, Colkesen ER, Visser JJ, Spronk S, Kraaijenhagen RA, et al. (2010) Systematic review of guidelines on cardiovascular risk assessment: Which recommendations should clinicians follow for a cardiovascular health check? Arch Intern Med 170: 27–40.
2. Greenland P, Smith SC, Jr., Grundy SM (2001) Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation 104: 1863–1867.
3. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, et al. (2005) Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 290: 890–894.
4. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, et al. (2003) Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290: 890–894.
5. Erson AE, Petty EM (2008) MicroRNAs in development and disease. Clin Genet 74: 296–306.
6. Zhang C (2008) MicroRNomics: a newly emerging approach for disease biology. Physiol Genomics 33: 139–147.
7. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857–866.
8. van RE, Olson EN (2007) MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 117: 2369–2376.
9. Tijssen AJ, Greemers EE, Moerland PD, de Windt LJ, van der Val AC, et al. (2010) MiR423-5p As a Circulating Biomarker for Heart Failure. Circ Res 106: 1035–1039.
10. Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, et al. (2011) Plasma MicroRNA 499 as a Biomarker of Acute Myocardial Infarction. Circ Res 108: 957–965.
11. Chen CZ, Li L, Lodish HF, Bartel DP (2004) MicroRNAs modulate hematopoietic lineage differentiation. Science 303: 83–86.
12. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, et al. (2005) Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 37: 766–770.
13. Chiang HR, Schornfeld LIV, Ruby JG, Anuyong VC, Spies N, et al. (2010) Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. Genes Dev 24: 992–1009.
14. Chen CZ, Li L, Lodish HF, Bartel DP (2004) MicroRNAs modulate hematopoietic lineage differentiation. Science 303: 83–86.
15. Bhattacharyya SN, Stiles CD, Kattman LM, Kuehl WM, Jr., et al. (2007) Platelet activation and atherothrombosis. N Engl J Med 357: 2482–2494.
16. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, et al. (2009) Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 16: 961–966.
17. Gilad S, Meiri E, Yoge Y, Benjamin S, Lebanony D, et al. (2008) Serum microRNAs are promising novel biomarkers. PLoS One 3: e3148.
18. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10353–10358.
19. Chen SY, Wang Y, Telen MJ, Chi JT (2008) The genomic analysis of erythrocyte microRNA expression in sickle cell diseases. PLoS One 3: e2360.
20. Bruchova H, Merkerova M, Bruchova H (2008) Differential expression of microRNAs in hematopoietic cell lineages. Eur J Haematol 81: 304–310.
21. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, et al. (2008) Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3: e3694.
22. Merkerova M, Belickova M, Bruchova H (2008) Differential expression of microRNAs in hematopoietic cell lineages. Eur J Haematol 81: 304–310.
23. Scheuner JT (2001) Genetic predisposition to coronary artery disease. Curr Opin Cardiol 16: 251–260.
24. Rodrigues AC, Li X, Radecki L, Pan YZ, Winter JC, et al. (2011) MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines.
25. Weber M, Baker MB, Patel RS, Qseyumi AA, Bao G, et al. (2011) MicroRNA Expression Profile in CAD Patients and the Impact of ACEI/ARB. Cardiol Res Pract 2011: 532915.
26. Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD (2005) Coronary Calcification, Coronary Disease Risk Factors, C-Reactive Protein, and Atherosclerotic Cardiovascular Disease Events: The St. Francis Heart Study. Journal of the American College of Cardiology 46: 158–165.
27. Ai J, Zhang R, Li Y, Pu J, Lu Y, et al. (2009) Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun.
28. Adachi T, Nakanishi M, Otsuka Y, Nishimura K, Hirokawa G, et al. (2010) MicroRNA 499 as a Biomarker of Acute Myocardial Infarction. Clin Chem 56: 1183–1185.
29. Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, et al. (2011) MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Research in Cardiology 106: 13–23.
30. Cortsen MF, Denuit R, Jochums S, Kazmentova T, Devaux Y, et al. (2010) Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease/Clinical Perspective. Circulation: Cardiovascular Genetics 3: 499–506.
31. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, et al. (2010) Circulating MicroRNAs in Patients With Coronary Artery Disease. Circ Res 107: 677–684.
32. Ji X, Takahashi Y, Hira Y, Hirokawa G, Fukushima Y, et al. (2009) Plasma miR-206 as a biomarker of myocardial injury. Clin Chem 55: 87–95.
33. Wang G, Zhu JQ, Zhang JT, Li Q, Li Y, et al. (2010) Circulating microRNA 499 as a novel potential biomarker for acute myocardial infarction. Biochem Biophys Res Commun.
34. Weber M, Baker MB, Patel RS, Qseyumi AA, Bao G, et al. (2011) MicroRNA Expression Profile in CAD Patients and the Impact of ACEI/ARB. Cardiol Res Pract 2011: 532915.
35. Scheuner JT (2001) Genetic predisposition to coronary artery disease. Curr Opin Cardiol 16: 251–260.
36. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, et al. (2010) MiR423-5p As a Circulating Biomarker for Heart Failure. Circ Res 106: 1035–1039.
37. Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, et al. (2011) MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Research in Cardiology 106: 13–23.
38. Cortsen MF, Denuit R, Jochums S, Kazmentova T, Devaux Y, et al. (2010) Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease/Clinical Perspective. Circulation: Cardiovascular Genetics 3: 499–506.
39. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, et al. (2010) Circulating MicroRNAs in Patients With Coronary Artery Disease. Circ Res 107: 677–684.
40. Ji X, Takahashi Y, Hira Y, Hirokawa G, Fukushima Y, et al. (2009) Plasma miR-206 as a biomarker of myocardial injury. Clin Chem 55: 87–95.
41. Wang G, Zhu J Q, Zhang J T, Li Q, Li Y, et al. (2010) Circulating microRNA 499 as a novel potential biomarker for acute myocardial infarction. Biochem Biophys Res Commun.
42. Murph TP, Bhargava R, Pencina MJ, Zafar AM, D’Agostino RB (2010) Performance of conventional guidelines for coronary heart disease prevention: Optimal use of the Framingham-based risk assessment. Atherosclerosis In Press, Corrected Proof.